8/102 sources · 2 publishersUpdated Nov 17, 21:21 UTC
Amneal Wins European Approval for Adcomfo Biosimilar
The European Commission authorized Amneal Pharmaceuticals’ Adcomfo, an omalizumab biosimilar to XOLAIR. The approval covers add-on treatment in several allergic conditions, and the supporting clinical program included a confirmatory study in 600 patients with chronic spontaneous urticaria. ADVANZ PHARMA holds European marketing authorization and regional commercialization rights, while Amneal’s U.S. application remains under FDA review.
Why it matters
The decision gives Adcomfo a regulatory pathway in Europe, with ADVANZ PHARMA responsible for regional commercialization. Amneal’s U.S. opportunity remains dependent on the FDA review.
Key facts
- 1The European Commission granted marketing authorization for Adcomfo in Europe. tradingview.com
- 2Adcomfo’s confirmatory clinical study enrolled 600 patients with chronic spontaneous urticaria and met its primary efficacy endpoint. tradingview.com
- 3ADVANZ PHARMA holds European marketing authorization and regional commercialization rights for Adcomfo. tradingview.com
- 4Amneal’s application for its proposed XOLAIR biosimilar is under review by the U.S. Food and Drug Administration. tradingview.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.